sur INVENTIVA (EPA:IVA)
Inventiva strengthens its leadership for phase 3 of lanifibranor
The biopharmaceutical company Inventiva announces the arrival of three new members to its management team. Axel-Sven Malkomes joins as Chief Financial Officer, Susan Coles as General Counsel, and Pamela Herbster as Chief Human Resources Officer.
These new hires come as Inventiva prepares to publish the results of its Phase 3 lanifibranor trial. Malkomes brings extensive experience in finance and acquisitions, having previously worked with BioNTech. Coles, with her expertise in life sciences law, previously worked for Vivet Therapeutics. Herbster, a human resources specialist, contributed to the success of Sage Therapeutics until its acquisition.
The company says it is ready to tackle this new stage with a strengthened team focused on key strategies and growth.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de INVENTIVA